Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2012 Filed Feb 27, 2012 22:46 UTC |
HILL CHARLES HExecutive Vice President
|
Tax withholdingCommon Stock | 2,869 | $21.18 | $60,765.42 |
DisclosureSEC source: 0001225208-12-005633 · doc4.xml · nonDerivative · entry 3 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,612 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 22:46 UTC |
HILL CHARLES HExecutive Vice President
|
GrantCommon Stock | 8,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005633 · doc4.xml · nonDerivative · entry 2 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,481 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 22:49 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 2,960 | $21.18 | $62,692.80 |
DisclosureSEC source: 0001225208-12-005634 · doc4.xml · nonDerivative · entry 4 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,099 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 22:49 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 2,901 | $21.18 | $61,443.18 |
DisclosureSEC source: 0001225208-12-005634 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,059 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 22:49 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantCommon Stock | 8,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005634 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,960 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 22:55 UTC |
PECK KRISTIN CExecutive Vice President
|
Tax withholdingCommon Stock | 3,044 | $21.18 | $64,471.92 |
DisclosureSEC source: 0001225208-12-005636 · doc4.xml · nonDerivative · entry 4 PECK KRISTIN C · CIK 0001488267 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,590 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 22:55 UTC |
PECK KRISTIN CExecutive Vice President
|
Tax withholdingCommon Stock | 2,983 | $21.18 | $63,179.94 |
DisclosureSEC source: 0001225208-12-005636 · doc4.xml · nonDerivative · entry 3 PECK KRISTIN C · CIK 0001488267 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,634 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 22:55 UTC |
PECK KRISTIN CExecutive Vice President
|
GrantCommon Stock | 8,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005636 · doc4.xml · nonDerivative · entry 2 PECK KRISTIN C · CIK 0001488267 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,617 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:01 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 33,885 | $21.18 | $717,684.30 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878,697 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:01 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantCommon Stock | 75,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912,582 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:12 UTC |
SCHULMAN AMY WExecutive Vice President
|
Tax withholdingCommon Stock | 18,990 | $21.18 | $402,208.20 |
DisclosureSEC source: 0001225208-12-005639 · doc4.xml · nonDerivative · entry 3 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,358 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:12 UTC |
SCHULMAN AMY WExecutive Vice President
|
GrantCommon Stock | 37,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005639 · doc4.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,348 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:14 UTC |
SIMMONS DAVID SBusiness Unit President
|
Tax withholdingCommon Stock | 7,483 | $21.18 | $158,489.94 |
DisclosureSEC source: 0001225208-12-005640 · doc4.xml · nonDerivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,880 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:14 UTC |
SIMMONS DAVID SBusiness Unit President
|
GrantCommon Stock | 16,618 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005640 · doc4.xml · nonDerivative · entry 2 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,363 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:17 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 24,809 | $21.18 | $525,454.62 |
DisclosureSEC source: 0001225208-12-005642 · doc4.xml · nonDerivative · entry 4 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,393 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:17 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 15,298 | $21.18 | $324,011.64 |
DisclosureSEC source: 0001225208-12-005642 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,202 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:17 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantCommon Stock | 30,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005642 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,500 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:31 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 144,033 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005625 · doc4.xml · derivative · entry 6 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,033 Underlying: Common Stock · 144,033 shares Expires 2019-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:31 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 169,903 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005625 · doc4.xml · derivative · entry 5 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,903 Underlying: Common Stock · 169,903 shares Expires 2017-02-23 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:31 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantCommon Stock | 32,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005625 · doc4.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,966 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:36 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 30,864 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005628 · doc4.xml · derivative · entry 7 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,864 Underlying: Common Stock · 30,864 shares Expires 2019-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:36 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 36,408 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005628 · doc4.xml · derivative · entry 6 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,408 Underlying: Common Stock · 36,408 shares Expires 2017-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:36 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 7,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005628 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,676 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:39 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 185,185 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005630 · doc4.xml · derivative · entry 7 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,185 Underlying: Common Stock · 185,185 shares Expires 2019-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:39 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 218,447 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005630 · doc4.xml · derivative · entry 6 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,447 Underlying: Common Stock · 218,447 shares Expires 2017-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:39 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantCommon Stock | 42,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005630 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,405 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:41 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 185,185 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005631 · doc4.xml · derivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,185 Underlying: Common Stock · 185,185 shares Expires 2019-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:41 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 218,447 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005631 · doc4.xml · derivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,447 Underlying: Common Stock · 218,447 shares Expires 2017-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:41 UTC |
Dolsten MikaelPresident R&D
|
GrantCommon Stock | 42,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005631 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,633 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:44 UTC |
Germano Geno JBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 144,033 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005632 · doc4.xml · derivative · entry 5 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,033 Underlying: Common Stock · 144,033 shares Expires 2019-02-23 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:44 UTC |
Germano Geno JBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 169,903 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005632 · doc4.xml · derivative · entry 4 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,903 Underlying: Common Stock · 169,903 shares Expires 2017-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:44 UTC |
Germano Geno JBusiness Unit President
|
GrantCommon Stock | 32,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005632 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,517 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:46 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 92,593 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005633 · doc4.xml · derivative · entry 7 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,593 Underlying: Common Stock · 92,593 shares Expires 2019-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:46 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 109,223 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005633 · doc4.xml · derivative · entry 6 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,223 Underlying: Common Stock · 109,223 shares Expires 2017-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:46 UTC |
HILL CHARLES HExecutive Vice President
|
GrantCommon Stock | 21,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005633 · doc4.xml · nonDerivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,438 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:49 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 43,724 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005634 · doc4.xml · derivative · entry 7 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,724 Underlying: Common Stock · 43,724 shares Expires 2019-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:49 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 51,578 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005634 · doc4.xml · derivative · entry 6 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,578 Underlying: Common Stock · 51,578 shares Expires 2017-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:49 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantCommon Stock | 10,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005634 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,954 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:51 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 87,449 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005635 · doc4.xml · derivative · entry 4 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,449 Underlying: Common Stock · 87,449 shares Expires 2019-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:51 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 103,155 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005635 · doc4.xml · derivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,155 Underlying: Common Stock · 103,155 shares Expires 2017-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:51 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantCommon Stock | 20,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005635 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,112 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:55 UTC |
PECK KRISTIN CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 43,724 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005636 · doc4.xml · derivative · entry 7 PECK KRISTIN C · CIK 0001488267 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,724 Underlying: Common Stock · 43,724 shares Expires 2019-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:55 UTC |
PECK KRISTIN CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 51,578 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005636 · doc4.xml · derivative · entry 6 PECK KRISTIN C · CIK 0001488267 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,578 Underlying: Common Stock · 51,578 shares Expires 2017-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 22:55 UTC |
PECK KRISTIN CExecutive Vice President
|
GrantCommon Stock | 10,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005636 · doc4.xml · nonDerivative · entry 1 PECK KRISTIN C · CIK 0001488267 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,384 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:01 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 668,724 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · derivative · entry 7 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,724 Underlying: Common Stock · 668,724 shares Expires 2019-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:01 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 788,835 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · derivative · entry 6 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,835 Underlying: Common Stock · 788,835 shares Expires 2017-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:01 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantCommon Stock | 153,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 837,331 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:04 UTC |
Redmond Cavan M.Group President
|
GrantStock Appreciation Rights · Derivative | 92,593 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005638 · doc4.xml · derivative · entry 5 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,593 Underlying: Common Stock · 92,593 shares Expires 2019-02-23 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:04 UTC |
Redmond Cavan M.Group President
|
GrantStock Appreciation Rights · Derivative | 109,223 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005638 · doc4.xml · derivative · entry 4 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,223 Underlying: Common Stock · 109,223 shares Expires 2017-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:04 UTC |
Redmond Cavan M.Group President
|
GrantCommon Stock | 21,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005638 · doc4.xml · nonDerivative · entry 1 Redmond Cavan M. · CIK 0001420120 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,138 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.